Antiandrogens Market Research Report: Information By Type (Steroidal and Nonsteroidal), By Disease Indication (Prostate Cancer, Benign Prostatic Hyperplasia, Hirsutism, Hyperandrogenism, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Table of Contents

1. Executive summary

2. Market Introduction

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. Research Methodology

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. Market Dynamics

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. Market Factor Analysis

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL ANTIANDROGENS MARKET, BY Type

6.1. Overview

6.2. Steroidal

6.3. Nonsteroidal

7. GLOBAL ANTIANDROGENS MARKET, BY Disease Indication

7.1. Overview

7.2. Prostate Cancer

7.3. Benign Prostatic Hyperplasia

7.4. Hirsutism

7.5. Hyperandrogenism

7.6. Others

8. GLOBAL ANTIANDROGENS MARKET, BY Distribution Channel

8.1. Overview

8.2. Hospital Pharmacies

8.3. Retail Pharmacies

8.4. Online Pharmacies

9. GLOBAL ANTIANDROGENS MARKET, by Region

9.1. Overview

9.1. North America

9.1.1. US

9.1.2. Canada

9.2. Europe

9.2.1. Germany

9.2.2. France

9.2.3. UK

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. South Korea

9.3.5. Australia

9.3.6. Rest of Asia-Pacific

9.4. Rest of the World

9.4.1. Middle East

9.4.2. Africa

9.4.3. Latin America

10. Competitive Landscape

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Antiandrogens Market,

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global Antiandrogens Market,

10.7. Key developments and Growth Strategies

10.7.1. New Product Launch/Service Deployment

10.7.2. Merger & Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income, 2022

10.8.2. Major Players R&D Expenditure. 2022

11. Company ProfileS

11.1. Pfizer Inc

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Astellas Pharma Inc.

11.2.1. Company Overview

11.2.2. Financial Overview

11.2.3. Products Offered

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. F. Hoffmann-La Roche Ltd.

11.3.1. Company Overview

11.3.2. Financial Overview

11.3.3. Products Offered

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. AstraZeneca Plc

11.4.1. Company Overview

11.4.2. Financial Overview

11.4.3. Products Offered

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Abbott Laboratories

11.5.1. Company Overview

11.5.2. Financial Overview

11.5.3. Products Offered

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Takeda Pharmaceutical Company Limited

11.6.1. Company Overview

11.6.2. Financial Overview

11.6.3. Products Offered

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. OSI Pharmaceuticals, Inc.

11.7.1. Company Overview

11.7.2. Financial Overview

11.7.3. Products Offered

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. GENENTECH INC.

11.8.1. Company Overview

11.8.2. Financial Overview

11.8.3. Products Offered

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Bristol-Myers Squibb Company

11.9.1. Company Overview

11.9.2. Financial Overview

11.9.3. Products Offered

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Novartis AG,

11.10.1. Company Overview

11.10.2. Financial Overview

11.10.3. Products Offered

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Progenics Pharmaceuticals, Inc

11.11.1. Company Overview

11.11.2. Financial Overview

11.11.3. Products Offered

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. ALZA Corporation

11.12.1. Company Overview

11.12.2. Financial Overview

11.12.3. Products Offered

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

11.13. Sanofi SA

11.13.1. Company Overview

11.13.2. Financial Overview

11.13.3. Products Offered

11.13.4. Key Developments

11.13.5. SWOT Analysis

11.13.6. Key Strategies

11.14. GlaxoSmithKline Plc

11.14.1. Company Overview

11.14.2. Financial Overview

11.14.3. Products Offered

11.14.4. Key Developments

11.14.5. SWOT Analysis

11.14.6. Key Strategies

11.15. Amgen Inc

11.15.1. Company Overview

11.15.2. Financial Overview

11.15.3. Products Offered

11.15.4. Key Developments

11.15.5. SWOT Analysis

11.15.6. Key Strategies

11.16. ANI Pharmaceuticals, Inc.

11.16.1. Company Overview

11.16.2. Financial Overview

11.16.3. Products Offered

11.16.4. Key Developments

11.16.5. SWOT Analysis

11.16.6. Key Strategies

12. Appendix

12.1. References

12.2. Related Reports

LIST OF TABLES

12.2.1. Global Antiandrogens Market, Synopsis, 2018-2032

TABLE 1 Global Antiandrogens Market, Estimates & Forecast, 2018-2032 (USD BILLION)

TABLE 2 GLOBAL ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 3 GLOBAL ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 4 GLOBAL ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 5 North America: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 6 North America: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 7 North America: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 8 US: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 9 US: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 10 US: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 11 Canada: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 12 Canada: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 13 Canada: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 14 Europe: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 15 Europe: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 16 Europe: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 17 germany: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 18 germany: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 19 germany: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 20 FRANCE: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 21 FRANCE: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 22 FRANCE: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 23 italy: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 24 italy: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 25 italy: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 26 spain: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 27 spain: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 28 spain: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 29 UK: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 30 UK: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 31 UK: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 32 rest of europe: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 33 rest of europe: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 34 rest of europe: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 35 Asia-Pacific: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 36 Asia-Pacific: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 37 Asia-Pacific: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 38 japan: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 39 japan: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 40 japan: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 41 china: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 42 china: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 43 china: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 44 india: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 45 india: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 46 india: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 47 australia: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 48 australia: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 49 australia: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 50 south korea: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 51 south korea: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 52 south korea: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 53 rest of asia-pacific: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 54 rest of asia-pacific: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 55 rest of asia-pacific: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 56 rest of the world: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 57 rest of the world: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 58 rest of the world: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 59 Middle east: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 60 Middle east: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 61 Middle east: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 62 Africa: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 63 Africa: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 64 Africa: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

TABLE 65 Latin america: ANTIANDROGENS MARKET, BY Type, 2018-2032 (USD BILLION)

TABLE 66 Latin america: ANTIANDROGENS MARKET, BY Disease Indication, 2018-2032 (USD BILLION)

TABLE 67 Latin america: ANTIANDROGENS MARKET, BY Distribution Channel, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 Research Process

FIGURE 2 Market Structure for the Global Antiandrogens Market

FIGURE 3 Market Dynamics for the Global Antiandrogens Market

FIGURE 4 Global Antiandrogens Market, Share (%), BY Type, 2022

FIGURE 5 Global Antiandrogens Market, Share (%), BY Disease Indication, 2022

FIGURE 6 Global Antiandrogens Market, Share (%), BY Distribution Channel, 2022

FIGURE 7 Global Antiandrogens Market, Share (%), by Region, 2022

FIGURE 8 north AMERICA: ANTIANDROGENS MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 Europe: ANTIANDROGENS MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 Asia-Pacific: ANTIANDROGENS MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 Rest of the world: ANTIANDROGENS MARKET, SHARE (%), BY REGION, 2022

FIGURE 12 Global Antiandrogens Market: Company Share Analysis, 2022 (%)

FIGURE 13 Pfizer Inc: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 14 Pfizer Inc: SWOT ANALYSIS

FIGURE 15 ASTELLAS PHARMA INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 16 ASTELLAS PHARMA INC.: SWOT ANALYSIS

FIGURE 17 F. Hoffmann-La Roche Ltd.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 18 F. Hoffmann-La Roche Ltd.: SWOT ANALYSIS

FIGURE 19 AstraZeneca Plc: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 20 AstraZeneca Plc: SWOT ANALYSIS

FIGURE 21 ABBOTT LABORATORIES.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 22 ABBOTT LABORATORIES.: SWOT ANALYSIS

FIGURE 23 Takeda Pharmaceutical Company Limited: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 Takeda Pharmaceutical Company Limited: SWOT ANALYSIS

FIGURE 25 OSI Pharmaceuticals, Inc.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 OSI Pharmaceuticals, Inc.: SWOT ANALYSIS

FIGURE 27 GENENTECH INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 GENENTECH INC.: SWOT ANALYSIS

FIGURE 29 Bristol-Myers Squibb Company: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 Bristol-Myers Squibb Company: SWOT ANALYSIS

FIGURE 31 Novartis AG,, Inc.rtis AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 Novartis AG,.rtis AG: SWOT ANALYSIS

FIGURE 33 Progenics Pharmaceuticals, Inc. FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 Progenics Pharmaceuticals, Inc.: SWOT ANALYSIS

FIGURE 35 ALZA Corporation: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 36 ALZA Corporation: SWOT ANALYSIS

FIGURE 37 Sanofi SA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 38 Sanofi SA: SWOT ANALYSIS

FIGURE 39 GlaxoSmithKline Plc: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 40 GlaxoSmithKline Plc: SWOT ANALYSIS

FIGURE 41 Amgen Inc,: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 42 Amgen Inc,: SWOT ANALYSIS

FIGURE 43 ANI Pharmaceuticals, Inc.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 44 ANI Pharmaceuticals, Inc.: SWOT ANALYSIS